Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
GermanyIn short
When a corneal transplant stops working as it should, patients face a challenging medical situation that requires prompt and specialized care. Understanding the available treatment options—from established medications to innovative approaches being tested in research—can help patients and their families navigate this complex condition.
Corneal graft failure happens when a transplanted cornea loses its ability to maintain clear vision. Although the cornea is considered an "immune privileged" tissue, meaning it's naturally protected from rejection more than other transplanted organs, the immune system can still attack the donor tissue. This immune response, called allogeneic rejection, is actually the most common reason why corneal transplants fail.
The success rate of corneal transplants depends heavily on individual patient circumstances. For first-time recipients whose corneal bed has no blood vessels, the two-year survival rate exceeds 90 percent. However, when patients have high-risk factors for rejection, this rate drops significantly to between 35 and 70 percent. Understanding these numbers helps patients appreciate the importance of careful monitoring and prompt treatment when problems arise.
Treatment goals for corneal graft failure center on preserving the transplant whenever possible, controlling symptoms like pain and light sensitivity, and maintaining or restoring useful vision. The approach taken depends on whether the failure is caught early, the type of transplant involved, and whether the patient has risk factors that make rejection more likely. Medical teams have access to well-established treatments proven through years of clinical use, as well as newer therapies being evaluated in clinical trials.
The distinction between "rejection" and "failure" is important to understand. Graft rejection describes the specific immune attack on the donor cornea, while graft failure is a broader term that describes any reason the transplant stops working—whether from rejection, infection, loss of essential cells, or other causes. Not all failures are caused by rejection, and not all rejection episodes lead to permanent failure if treated quickly.
When doctors diagnose corneal graft rejection, topical corticosteroids form the backbone of treatment. These anti-inflammatory medications work by suppressing the immune system's attack on the transplanted cornea. The specific medication, frequency of use, and duration all depend on which part of the cornea is being rejected and how severe the rejection episode is.
For epithelial rejection or stromal rejection—types that affect the surface or middle layers of the cornea without involving the critical inner layer—treatment typically involves topical corticosteroid drops such as dexamethasone 0.1% or prednisolone acetate 1%. Patients apply these drops four to six times daily until signs of rejection disappear. Even though epithelial rejection may sometimes resolve on its own, doctors treat it aggressively because it signals that the immune system has recognized the graft as foreign, which could lead to more serious problems.
Endothelial rejection represents the most serious form because it attacks the endothelial cells, which are absolutely critical for keeping the cornea clear. Human endothelial cells cannot regenerate through cell division, so when they're lost, they're gone permanently. If the cell count drops below a critical threshold, the cornea swells and becomes cloudy. This type of rejection requires much more intensive treatment.
For endothelial rejection, patients use corticosteroid eye drops every hour while awake, and as frequently as possible during the night for the first two to three days. After this intensive period, the frequency reduces to every two hours while awake. Some doctors also prescribe high-potency corticosteroids like difluprednate. Additionally, steroid ointment may be applied at bedtime. This aggressive treatment continues until rejection signs resolve, then gradually tapers over several weeks to months.
When rejection is severe, recurrent, or occurs in high-risk patients (such as those with vascularized corneas or previous chemical burns), additional routes of corticosteroid administration may be needed. Doctors can inject corticosteroids directly under the conjunctiva using medications like dexamethasone phosphate (2 mg) or betamethasone (3 mg). Another option involves placing a collagen shield soaked in corticosteroids on the cornea, which acts as a reservoir that slowly releases medication between eye drop applications.
In severe or high-risk cases, systemic corticosteroids or immunosuppressants become necessary. Oral prednisone typically starts at 60 to 80 mg daily and continues for one to two weeks before gradually decreasing. An alternative approach uses pulsed intravenous steroids—a single dose of 500 mg methylprednisolone. Research has shown that patients who receive pulsed steroids within the first eight days of a rejection episode have better graft survival rates compared to those receiving oral steroids. Additionally, pulsed steroids reduce the risk of future rejection episodes and avoid the side effects associated with prolonged oral steroid use.
Throughout any rejection treatment, careful monitoring of eye pressure is essential because corticosteroids can cause increased pressure inside the eye, potentially leading to glaucoma. Doctors regularly check pressure levels and adjust treatment if necessary.
For patients identified as high-risk before rejection occurs, preventive treatment may include topical cyclosporine. This immunosuppressive medication works differently from steroids by targeting specific immune cells called T-cells. Some high-risk patients may receive combination therapy using multiple immunosuppressive agents to prevent rejection from occurring in the first place.
Side effects from corticosteroid treatment can include increased eye pressure, cataract formation, delayed wound healing, and increased infection risk. With systemic steroids, patients may experience weight gain, mood changes, elevated blood sugar, weakened bones, and increased susceptibility to infections. The medical team weighs these risks against the benefit of saving the transplant when deciding on treatment intensity.
While standard corticosteroid therapy remains the foundation of treatment, researchers are actively investigating new approaches to prevent and treat corneal graft rejection. These clinical trials explore different mechanisms of suppressing the immune response while potentially reducing side effects compared to traditional treatments.
Combination immunosuppression regimens are being studied in patients at very high risk of rejection, particularly those who have already lost multiple corneal transplants. One approach involves using three medications together: oral prednisone, azathioprine (an antimetabolite that interferes with immune cell reproduction), and cyclosporine (a calcineurin inhibitor that blocks T-cell activation). In case series reports, patients receiving this triple therapy maintained clear grafts over observation periods averaging 37 months, with minimal adverse effects.
The rationale behind combination therapy is that using multiple agents at lower doses may provide better immune suppression than a single agent at a higher dose, while potentially reducing the side effect profile. This approach is similar to strategies used successfully in kidney and heart transplantation, adapted for the unique characteristics of corneal transplants.
Topical immunosuppressive agents beyond cyclosporine are also being evaluated. Tacrolimus (also known as FK506), another calcineurin inhibitor, has been studied for long-term use in high-risk penetrating keratoplasty. Studies have examined whether this medication, applied as eye drops, can prevent rejection in patients with vascularized corneas or those undergoing repeat transplantation.
Research is also focused on understanding how different types of corneal transplant procedures affect rejection risk. Newer techniques like Descemet stripping endothelial keratoplasty (DSEK/DSAEK) and Descemet membrane endothelial keratoplasty (DMEK) replace only the damaged inner layer of the cornea rather than the full thickness. These procedures expose the immune system to less donor tissue, which theoretically should reduce rejection risk. Clinical trials have shown that DMEK significantly reduces the risk of corneal transplant rejection compared to full-thickness penetrating keratoplasty.
Deep anterior lamellar keratoplasty (DALK) represents another selective approach that replaces only the front layers of the cornea while preserving the patient's own endothelial cells. Since endothelial rejection is the most serious type, avoiding transplantation of this layer dramatically reduces rejection risk. Studies report rejection rates following DALK ranging from 6 to 19.7 percent, compared to higher rates with full-thickness transplants.
Researchers are also investigating synthetic or bioengineered alternatives to human corneal tissue. These laboratory-created corneas could potentially eliminate rejection risk entirely since they wouldn't contain foreign cells that trigger an immune response. While still in relatively early phases of development, these technologies represent a promising future direction for patients who might otherwise face repeated transplant failures.
Another area of clinical investigation involves optimizing the timing and intensity of steroid treatment protocols. Some trials compare different steroid dosing regimens to determine the minimum effective treatment that prevents rejection while minimizing side effects. Other studies examine how quickly steroids can be tapered after transplantation in low-risk versus high-risk patients.
The development of better predictive tools also represents an important research direction. Scientists are working to identify biomarkers—measurable indicators in blood, tears, or corneal tissue—that could predict which patients are most likely to reject their grafts. This would allow doctors to provide more intensive preventive treatment to high-risk individuals while sparing low-risk patients from unnecessary medication exposure.
Clinical trials examining corneal graft rejection are conducted at major ophthalmology centers across the United States, Europe, and other regions worldwide. Patients interested in participating can discuss options with their ophthalmologist, who can provide information about trials recruiting patients with their specific circumstances.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
